Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®

Sun Pharma, a global pharmaceutical company with a growing portfolio of Innovative Medicines, today announced it acquired, at ...

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in ...

Europe Photodynamic Therapy Market Size, Trends, Leading Applications and Pricing Benchmarks (2025-2033) Featuring Gladerma, Sun Pharmaceutical, Biofrontera, Lum…

The "Europe Photodynamic Therapy Market Size and Trends 2025-2033" has been added to ResearchAndMarkets.com's offering. The ...
Agence France-Presse

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

Actinic keratosis affects more than 10% of Europeans and is considered the most common pre-cancerous dermatological condition driven by an overactive PI3K/mTOR pathway. Bimiralisib gel is a selective ...
Seeking Alpha

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...